Articles

by Kenny Dolgin, Data Insights, Guidepoint Penumbra Inc. (NYSE: PEN) is a key player in the treatment for ischemic stroke, having received FDA approval for the first aspiration-based thrombectomy system in 2007 and having since launched five new generations of…

Guidepoint works with over 3,250 clients, including 9 of the top 10 global consulting firms.   Our network is made up of over 900,000 Advisors covering all sectors, regions and relevant industries. These Advisors are C-Suite Decision Makers, Customers, Suppliers,…

by Ken Wahl, Data Insights, Guidepoint Shire Plc’s (NYSE: SHPG) US hemophilia sales have faced much competition in recent years. In particular, their leading hemophilia A treatment Advate, an older, shorter-acting recombinant factor VIII, is facing many new US market…